The present disclosure relates to neural electrode technology for measuring a biosignal of a human or applying a neural signal to the human, and a neural electrode assembly includes a body that is inserted into a uterus in a non-invasive manner, a recording neural electrode formed to measure a uterine contraction-evoked neural signal, the recording neural electrode being coupled to the body, and a stimulating neural electrode formed to stimulate a nerve entering the uterus to suppress the uterine contraction, the stimulating neural electrode being coupled to the body.

In some examples, a method including determining a chronaxie of evoked threshold motor responses from electrical stimulation delivered to a sacral nerve of a patient; and delivering, based on the determined chronaxie, electrical stimulation therapy, configured to treat a patient condition, to the sacral nerve having a pulse width at or near the identified chronaxie, wherein the delivered electrical stimulation is configured to inhibit contraction of at least one a bladder or bowel of the patient.

Nerve stimulation systems and methods are disclosed for providing improved compliance of a patient to a pelvic disorder treatment regimen. A patient interface module is connected to a control module for providing compliance information related to compliance criteria for a set of scheduled events. Patient compliance is assessed and notification or treatment events can be scheduled, rescheduled or otherwise adjusted based upon patient compliance or non-compliance according to compliance rules and parameters of a treatment compliance module. Both compliance and non-compliance may lead to adjustment of the treatment regimen, scheduled treatment events, and notifications to the patient or user operating the nerve stimulation system.

A system for treating chronic inflammation may include an implantable microstimulator, a wearable charger, and optionally an external controller. The implantable microstimulator may be implemented as a leadless neurostimulator implantable in communication with a cervical region of a vagus nerve. The microstimulator can address several types of stimulation including regular dose delivery. The wearable charger may be worn around the subject's neck to rapidly (<10 minutes per week) charge an implanted microstimulator. The external controller may be configured as a prescription pad that controls the dosing and activity of the microstimulator.

An electrode is provided that includes a wire that has a wire diameter of between 75 and 125 microns. The electrode includes a non-electrically-insulated current-application longitudinal segment, which, in the absence of any applied forces, is coiled and has (i) an outer coil diameter of between 3 and 7 times the wire diameter, and (ii) an entire longitudinal length of between 5 and 35 mm. The electrode further includes an electrically-insulated lead longitudinal segment, which has an entire longitudinal length of at least 10 mm, in the absence of any applied forces. Other embodiments are also described.

Devices, systems, and techniques for controlling electrical stimulation therapy are described. In one example, a system may be configured to deliver electrical stimulation therapy to a patient, the electrical stimulation therapy comprising a plurality of therapy pulses at a predetermined pulse frequency over a period of tune and deliver, over the period of time, a plurality of control pulses interleaved with at least some therapy pulses of the plurality of therapy pulses. The system may also be configured to sense, after one or more control pulses and prior to an immediately subsequent therapy pulse of the plurality of therapy pulses, a respective evoked compound action potential (ECAP), adjust, based on at least one respective ECAP, one or more parameter values that at least partially defines the plurality of therapy pulses, and deliver the electrical stimulation therapy to the patient according to the adjusted one or more parameter values.

Diagnostic screening tests that can be used to identify if a patient is a good candidates for an implantable vagus nerve stimulation device. One or more analyte, such as a cytokine or inflammatory molecule, can be measured from a blood sample taken prior to implantation of a vagus nerve stimulator to determine the patient's responsiveness to VNS for treatment of an inflammatory disorder.

An arrangement for reducing intraocular pressure includes a pulse signal source, a probe coupling, and at least one electrode. The probe coupling is configured to be supported on a portion of a living eye. The electrodes are supported on the probe coupling. The electrodes are operably coupled to receive a pulse signal from the pulse signal source.

The present invention relates to a system and method, in which a distal end of an electrode is implanted in an organ, such as a pituitary gland, for intermittent electrical stimulation thereof and a proximal end of the electrode is provided with a connection plug, a distal end of which can be attached to a bone adjacent the organ, such an anterior wall of the sphenoid sinus/vomer, and a proximal end of which can be reversibly connected electrically to a wire that is connected electrically to a source of electrical stimulation for the organ.

The present disclosure provides systems and methods for targeted nerve stimulation. In particular, the present disclosure provides systems and methods for determining the location of electrode placement providing the most therapeutic benefit for a particular subject. The various embodiments disclosed herein include methods for identifying a target nerve having the strongest representation and/or the strongest subject perception associated with a peripheral nerve in a patient-specific manner.